Citations

Clear

912 citation(s) found for "Yu, Caroline".

Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome
Villalba, Julian A. , Hilburn, Caroline F., Garlin, Michelle A., Elliott, Grant A., Li, Yijia , Kunitoki, Keiko , Poli, Sergio , Alba, George A. , Taso, Manuel , Price, Melissa C. , Aviles, Alexis J., Araujo-Medina, Milagros, Bonanno, Liana, Boyraz, Bariş , Champion, Samantha N. , Harris, Cynthia K. , Helland, T. Leif , Hutchison, Bailey , Jobbagy, Soma , Shepherd, Daniel , Barth, Jaimie L., Hung, Yin P. , Ly, Amy , Turbett, Sarah E. , Pierce, Virginia , Branda, John A. , Rosenberg, Eric , Mendez-Pena, Javier E., Chebib, Ivan , Rosales, Ivy A. , Smith, R. Neal , Miller, Miles A. , Rosas, Iván O. , Hardin, C. Corey , Baden, Lindsey R. , Stone, James R. , Shih, Angela , Politis, Michelle Garlin , Little, Brent P. , Hung, Yin P , Miller, Miles A , Garlin Politis, Michelle , Madrigal, Emilio , Marshall, Michael S. , Hariri, Lida P. , Medoff, Benjamin D. , Colvin, Robert B. , Mino-Kenudson, Mari A. , Shih, Angela

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 7, 2022 | Volume: 206 | Issue: 7 | Pages: 857-873

10.1164/rccm.202109-2150oc | PMID 35671465 Get It

Abstract Rationale The leading cause of death in coronavirus disease 2019 (COVID-19) is severe pneumonia, with many patients developing acute respiratory distress syndrome (ARDS) and diffuse alveolar damage (DAD). Whether DAD in fatal COVID-19 is distinct from other causes of DAD remains unknown. Objective To compare lung parenchymal and vascular alterations between patients with fatal COVID-19 pneumonia and other DAD-causing etiologies using a multidimensional approach. Methods This autopsy cohort consisted of consecutive patients with COVID-19 pneumonia (n = 20) and with respiratory failure and histologic DAD (n = 21; non–COVID-19 viral and nonviral etiologies). Premortem chest computed tomography (CT) scans were evaluated for vascular changes. Postmortem lung tissues were compared using histopathological and computational analyses. Machine-learning-derived morphometric analysis of the microvasculature was performed, with a random forest classifier quantifying vascular congestion (CVasc) in different microscopic compartments. Respiratory mechanics and gas-exchange parameters were evaluated longitudinally in patients with ARDS. Measurements and Main Results In premortem CT, patients with COVID-19 showed more dilated vasculature when all lung segments were evaluated (P = 0.001) compared with controls with DAD. Histopathology revealed vasculopathic changes, including hemangiomatosis-like changes (P = 0.043), thromboemboli (P = 0.0038), pulmonary infarcts (P = 0.047), and perivascular inflammation (P < 0.001). Generalized estimating equations revealed significant regional differences in the lung microarchitecture among all DAD-causing entities. COVID-19 showed a larger overall CVasc range (P = 0.002). Alveolar-septal congestion was associated with a significantly shorter time to death from symptom onset (P = 0.03), length of hospital stay (P = 0.02), and increased ventilatory ratio [an estimate for pulmonary dead space fraction (Vd); p = 0.043] in all cases of ARDS. Conclusions Severe COVID-19 pneumonia is characterized by significant vasculopathy and aberrant alveolar-septal congestion. Our findings also highlight the role that vascular alterations may play in Vd and clinical outcomes in ARDS in general.
Using cell-free circulating tumor DNA (cfDNA) to identify guideline-relevant biomarkers for therapy selection in 14,000 patients (pts) with metastatic colorectal cancer (mCRC).
Tan, Benjamin , Nguyen, Timmy, Starr, Jason S. , Drusbosky, Leylah , Weipert, Caroline , Kasi, Pashtoon Murtaza , Bucheit, Leslie

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 3601-3601

10.1200/jco.2022.40.16_suppl.3601 Get It

3601 Background: Two cfDNA assays are FDA-approved for use in advanced cancer pts across solid tumors. While several NCCN guidelines recommend cfDNA as a valid and useful method for molecular testing, the utility varies by cancer type. Despite the growing number of molecular alterations pertinent to first-line treatment in mCRC, current guidelines offer little guidance on the use of cfDNA in mCRC. Here we assess the ability of cfDNA to detect guideline-relevant actionable biomarkers informative for first-line therapy selection and beyond in patients with mCRC. Methods: We queried consecutive samples from advanced cancer pts with a diagnosis of CRC who underwent testing via a commercially available cfDNA assay (Guardant360) from September 2018 to January 2022. Validation and content of this assay has been previously described. To enrich for less heavily treated pts, we limited analysis to those whose first cfDNA test was done during the study period and only included the pt’s first test. The maximum variant allele fraction (maxVAF) for each test was used as a proxy for tumor shed and was compared between cancers with a Mann-Whitney test. The frequency of suspected germline alterations was assessed only in pts who received testing via a panel version with expanded mismatch repair (MMR) gene coverage. Tissue frequencies for select biomarkers were obtained from the MSK-IMPACT Clinical Sequencing Cohort in cBioPortal. Results: In total, 14,345 pts with mCRC received their first cfDNA test during the study period, with 92% of pts (13,190) having >1 cfDNA alteration detected. Median age was 62 and 44% of pts were female. The frequencies of key biomarkers are listed in Table 1. The median maxVAF was 5.6%, compared to 2.5% and 1.8% for pts with advanced gastric and NSCLC, respectively (p = < 0.0001 for both). The average turnaround time (TAT) for tests was 7 calendar days. Conclusions: cfDNA results from pts with mCRC demonstrated detection of biomarkers essential to first-line treatment decisions at a frequency comparable to what has been reported via tissue genotyping. mCRC pts had significantly higher tumor shed compared to other cancer types with guidelines that recommend cfDNA as an option for molecular testing, suggesting a potential gap in coverage. Tissue availability in mCRC does not guarantee comprehensive testing is completed quickly (compared to the 7-day TAT seen for cfDNA here), making it an attractive alternative strategy for first-line therapy selection in mCRC. [Table: see text]
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).
Ahnert, Jordi Rodon, Misleh, Jamal , Lim, Kian-Huat, Chiorean, E. Gabriela , Pishvaian, Michael J. , McKean, Heidi, Kreider, Brent, Knoerzer, Deb, Groover, Anna, Varterasian, Mary , Box, Jessica A., Emery, Caroline, Sullivan, Ryan J. , Burkard, Mark E. , McKean, Meredith Ann , Ahnert, Jordi Rodon, Mettu, Niharika B , Jones, Jeremy C , Wee, Wen , Lim, Kian-Huat , Gadgeel, Shirish M. , Kreider, Brent, Emery, Caroline

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS3172-TPS3172

10.1200/jco.2022.40.16_suppl.tps3172 Get It

TPS3172 Background: Ulixertinib (BVD-523) is a small molecule inhibitor of extracellular signal-regulated kinases 1/2 (ERK1/2) in development as a novel anti-cancer drug. Early clinical data demonstrated anti-tumor activity, especially for patients with tumors harboring atypical BRAF or MEK1/2 alterations (Sullivan et al., Cancer Discov. 2018;8(2):184-195). Atypical BRAF (non-V600) alterations can be categorized according to characteristics of molecular signaling (Class II or III), are seen in approximately 3% of all human cancers, and there are currently no approved therapies for this indication. Similar to atypical BRAF alterations, the incidence of MEK1/2 alterations are rare in human tumors (< 1 %). Preclinical data have demonstrated activity of ulixertinib in MEK mutant models. Ulixertinib has FDA fast-track designation for patients with solid tumors, other than CRC, with specific BRAF mutations (G469A, L485W, or L597Q). Designed with intent to register, the BVD-523-ABC clinical trial will continue evaluation of ulixertinib in patients with tumors harboring any atypical BRAF or MEK1/2 alteration (NCT04488003). Methods: This multi-center, phase II study, will be conducted in two parts and assess the clinical benefit, safety, pharmacokinetics, and pharmacodynamics of ulixertinib in patients with advanced malignancies. Ulixertinib will be administered at the RP2D of 600 mg BID for 28-day treatment cycles. Eligible patients will have locally advanced or metastatic cancer which progressed following standard systemic therapies, or for which the patient is not a candidate or refused systemic therapy. Planned correlative analyses include reverse phase protein array and transcriptomics of tumor tissue. Part A is open-label and tumor agnostic, except for group 4 and 6 (CRC patients only). Patients will enroll into one of six groups based on BRAF (groups 1-4) or MEK1/2 (groups 5-6) tumor alteration (38 patients per group). Overall response rate (ORR) is the primary endpoint for Part A, with secondary endpoints including duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Part B is tumor histology specific. Patients will be randomized to receive either ulixertinib or physician's choice of treatment in a 2:1 ratio. Up to three specified tumor histologies will be defined, guided by available Part A data (n = 80-100 per histology). The primary endpoint of Part B is PFS, and secondary endpoints include OS, ORR, and DOR. This study has enrolled 43 patients of the planned 228 in Part A at the time of abstract submission. Clinical trial information: NCT04488003.
Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
Sendi, Parham , Thierstein, Marc, Widmer, Nadja , Bosombo, Flora Babongo, Büchi, Annina Elisabeth , Güntensperger, Dominik , Tinguely, Caroline , Gahl, Brigitta , Heg, Dik , Theel, Elitza S. , Berbari, Elie F. , Niederhauser, Christoph , study, for the PoliCOV‐19, Berbari, Elie, Gahl, Brigitta , Büchi, Annina Elisabeth , Sendi, Parham , Blum, Manuel R. , Baldan, Rossella , Endimiani, Andrea , Gowland, Peter , study, for the PoliCOV‐19

Mayo Clinic

Immunity, Inflammation and Disease | June 6, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/iid3.640 | PMID 35759237 Get It

AbstractIntroductionTo assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign.MethodsThe cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires.ResultsThe mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose.ConclusionThese data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals.
Outcomes of dual kidney transplants from high KDPI kidneys are superior compared to single kidney high KDPI transplants at 1 year
Das, Devika , Wagler, Josiah , Ohara, Stephanie , Nguyen, Michelle , Frasco, Peter E. , Smith, Maxwell L. , Khamash, Hasan , Mathur, Amit K. , Budhiraja, Pooja , Reddy, Kunam S. , Heilman, Raymond L. , Smith, Maxwell , Reddy, Kunam S , Heilman, Raymond , Jadlowiec, Caroline , Das, Devika , Ohara, Stephanie Y , Budhiraja, Pooja , Nguyen, Michelle C , Jadlowiec, Caroline C.

Mayo Clinic

Clinical Transplantation | May 28, 2022 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/ctr.14737 | PMID 35633507 Get It

AbstractDual kidney transplantation (DKT), utilizing two adult kidneys from the same donor for one recipient, has been used as a way to expand the available donor pool. These kidneys often come from high Kidney Donor Profile Index donors (KDPI > 85%). Data comparing outcomes between high KDPI DKT and single kidney transplants (SKT) remain limited. We assessed outcomes of 336 high KDPI kidney transplants performed at our center; 11.0% (n = 37) were DKT. Recipients of DKT were older (P = .02) and donors had a higher KDPI score (median 96% vs. 91%, P < .0001). DKT operative time was higher compared to SKT (+1.4 hours, P < .0001). There were no differences in delayed graft function (54.1% vs. 51.5%, P = .77) and hospital length of stay (median 4.0 vs. 3.0 days, P = .21) between DKT and SKT. Grade I Clavien‐Dindo complications occurred in 8.1% of DKT and 13.7% of SKT (P = .008). There were no grade IVa, IVb, or V complications in either group. DKT had more glomerulosclerosis (P = .04), interstitial fibrosis (P = .02), tubular atrophy (P = .01), and arterial thickening (P = .03) on 1‐year protocol biopsies. Estimated glomerular filtration was higher for DKT at 1‐ (P = .004) and 2‐years post‐transplant (P = .01). There were no differences in patient (HR 1.3, 95% CI .5‐3.3, P = .58) or graft (HR 1.1, 95% CI .5‐2.3, P = .83) survival. Good outcomes can be achieved with DKT using high KDPI kidneys with moderate chronic changes. DKT is a good option to help further utilize high KDPI kidneys and minimize discard.
Distinct Phenotypes of Kidney Transplant Recipients in the United States with Limited Functional Status as Identified through Machine Learning Consensus Clustering
Jadlowiec, Caroline C. , Kaewput, Wisit , Vaitla, Pradeep , Mao, Shennen A. , Mao, Michael A. , Leeaphorn, Napat , Pattharanitima, Pattharawin , Qureshi, Fahad , Acharya, Prakrati , Cooper, Matthew , Cheungpasitporn, Wisit , Jadlowiec, Caroline , Kaewput, Wisit , Mao, Shennen A , Mao, Michael A , Pattharanitima, Pattharawin , Qureshi, Fahad , Cooper, Matthew , Cheungpasitporn, Wisit , Thongprayoon, Charat , Qureshi, Fawad , Nissaisorakarn, Pitchaphon

Mayo Clinic

Journal of Personalized Medicine | May 25, 2022 | Volume: 12 | Issue: 6 | Pages: 859

10.3390/jpm12060859 | PMID 35743647 Get It

Background: There have been concerns regarding increased perioperative mortality, length of hospital stay, and rates of graft loss in kidney transplant recipients with functional limitations. The application of machine learning consensus clustering approach may provide a novel understanding of unique phenotypes of functionally limited kidney transplant recipients with distinct outcomes in order to identify strategies to improve outcomes. Methods: Consensus cluster analysis was performed based on recipient-, donor-, and transplant-related characteristics in 3205 functionally limited kidney transplant recipients (Karnofsky Performance Scale (KPS) < 40% at transplant) in the OPTN/UNOS database from 2010 to 2019. Each cluster’s key characteristics were identified using the standardized mean difference. Posttransplant outcomes, including death-censored graft failure, patient death, and acute allograft rejection were compared among the clusters Results: Consensus cluster analysis identified two distinct clusters that best represented the clinical characteristics of kidney transplant recipients with limited functional status prior to transplant. Cluster 1 patients were older in age and were more likely to receive deceased donor kidney transplant with a higher number of HLA mismatches. In contrast, cluster 2 patients were younger, had shorter dialysis duration, were more likely to be retransplants, and were more likely to receive living donor kidney transplants from HLA mismatched donors. As such, cluster 2 recipients had a higher PRA, less cold ischemia time, and lower proportion of machine-perfused kidneys. Despite having a low KPS, 5-year patient survival was 79.1 and 83.9% for clusters 1 and 2; 5-year death-censored graft survival was 86.9 and 91.9%. Cluster 1 had lower death-censored graft survival and patient survival but higher acute rejection, compared to cluster 2. Conclusion: Our study used an unsupervised machine learning approach to characterize kidney transplant recipients with limited functional status into two clinically distinct clusters with differing posttransplant outcomes.
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, Caroline, Azemawah, Veronica, Hashemzadeh, Mehrnoosh , Hashemzadeh, Mehrnoosh , Movahed, Mohammad Reza , Peyton, Lee , Gregory, James

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | May 20, 2022 | Volume: 27 | Issue: No issue available | Pages: No page available

10.1177/10742484221100107 | PMID 35593194 Get It

Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do not achieve their treatment goals while on high-intensity statin therapy, such as those with familial hypercholesterolemia, remain at risk. With the discovery of PCSK9 inhibitors, the ability to provide more aggressive treatment for patients with homozygous and heterozygous familial hypercholesterolemia has increased. Ezetimibe reduces LDL-C by 15%-20% when combined with statin. 2 , 3 Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been found to achieve profound reductions in LDL-C (54%-74%) when added to statins. They have shown dramatic effects at lowering major adverse cardiovascular events (MACE) in high-risk patients 4 with LDL-C levels ≥70 mg/dL and can be used in populations that are statin intolerant or not at goal levels with maximally tolerated statin therapy. PCSK9 inhibitors also produce minimal side effects. Myopathy, a common side effect for patients on statins, has been rare in patients on PCSK9 inhibitors. Randomized trials have shown that reduction in LDL-C has translated to clinical benefits even in patients who have not achieved their LDL-C target.
Familial Recurrence Patterns in Congenitally Corrected Transposition of the Great Arteries: An International Study
Tortigue, Marine , Nield, Lynne E. , Karakachoff, Matilde , McLeod, Christopher J. , Belli, Emré , Babu‐Narayan, Sonya V. , Prigent, Solène , Conway, Miriam, Elder, Robert W. , Ladouceur, Magalie , Kowalik, Ewa , Kalfa, David , Mussa, Shafi, Hiippala, Anita , Temple, Joel , Abadir, Sylvia , Gloan, Laurianne Le , Lachaud, Matthias , Sanatani, Shubhayan , Thambo, Jean‐Benoît , Gronier, Céline, Charbonneau, Anne, Koutbi, Linda , Houeijeh, Ali , Combes, Nicolas , Duthoit, Guillaume, Hiel, Bérengère, Erickson, Christopher C. , Bonnet, Caroline , Hare, George F. Van , Dina, Christian , Fournier, Emmanuelle , Bloa, Mathieu Le , Pass, Robert H. , Liberman, Leonardo , Happonen, Juha-Matti, Perry, James C. , Romefort, Bénédicte, Benbrik, Nadir , Hauet, Quentin , Fraisse, Alain , Dubin, Anne M. , Ho, Siew Yen , Redon, Richard , Bacha, Emile , Elder, Robert W , Ladouceur, Magalie , Khairy, Paul , Kowalik, Ewa , Barron, David J , Sanatani, Shubhayan , Amedro, Pascal , Vaksmann, Guy , Ovaert, Caroline , Houeijeh, Ali , Combes, Nicolas , Maury, Philippe , Erickson, Christopher C , Van Hare, George F , Dina, Christian , Fournier, Emmanuelle , Le Bloa, Mathieu , Perry, James C , Benbrik, Nadir , Abrams, Dominic J , Dubin, Anne M , Ho, Siew Yen , Redon, Richard , Baruteau, Alban-Elouen , McLeod, Christopher J , Karakachoff, Matilde , Nield, Lynne E , Babu-Narayan, Sonya V , Belli, Emre , Boët, Angèle , Charbonneau, Anne, Maury, Philippe , Bonnet, Caroline, Karsenty, Clément , Gatzoulis, Michael Α. , Abrams, Dominic J. , Schott, Jean‐Jacques , Baruteau, Alban‐Elouen

Mayo Clinic

Circulation: Genomic and Precision Medicine | May 12, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circgen.121.003464 | PMID 35549293 Get It

Background: Congenitally corrected transposition of the great arteries (ccTGA) is a rare disease of unknown cause. We aimed to better understand familial recurrence patterns. Methods: An international, multicentre, retrospective cohort study was conducted in 29 tertiary hospitals in 6 countries between 1990 and 2018, entailing investigation of 1043 unrelated ccTGA probands. Results: Laterality defects and atrioventricular block at diagnosis were observed in 29.9% and 9.3%, respectively. ccTGA was associated with primary ciliary dyskinesia in 11 patients. Parental consanguinity was noted in 3.4% cases. A congenital heart defect was diagnosed in 81 relatives from 69 families, 58% of them being first-degree relatives, including 28 siblings. The most prevalent defects in relatives were dextro-transposition of the great arteries (28.4%), laterality defects (13.6%), and ccTGA (11.1%); 36 new familial clusters were described, including 8 pedigrees with concordant familial aggregation of ccTGA, 19 pedigrees with familial co-segregation of ccTGA and dextro-transposition of the great arteries, and 9 familial co-segregation of ccTGA and laterality defects. In one family co-segregation of ccTGA, dextro-transposition of the great arteries and heterotaxy syndrome in 3 distinct relatives was found. In another family, twins both displayed ccTGA and primary ciliary dyskinesia. Conclusions: ccTGA is not always a sporadic congenital heart defect. Familial clusters as well as evidence of an association between ccTGA, dextro-transposition of the great arteries, laterality defects and in some cases primary ciliary dyskinesia, strongly suggest a common pathogenetic pathway involving laterality genes in the pathophysiology of ccTGA.
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
Broder, Joshua , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Freiermuth, Caroline E. , Griffey, Richard T. , Hooker, Edmond A. , Jang, Timothy , Meltzer, Andrew C. , Pepper, Joan D., Prakken, Steven, Upadhye, Suneel , Broder, Joshua S , Oliveira J E Silva, Lucas , Hooker, Edmond , Jang, Timothy B , Mills, Angela M , Repplinger, Michael D , Upadhye, Suneel , Carpenter, Christopher R , Bellolio, M Fernanda , Griffey, Richard T , Meltzer, Andrew C , Mills, Angela M. , Carpenter, Christopher R.

Mayo Clinic

Academic Emergency Medicine | May 11, 2022 | Volume: 29 | Issue: 5 | Pages: 526-560

10.1111/acem.14495 | PMID 35543712 Get It

AbstractThis second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARYThe GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
Use of Machine Learning Consensus Clustering to Identify Distinct Subtypes of Black Kidney Transplant Recipients and Associated Outcomes
Vaitla, Pradeep , Leeaphorn, Napat , Pattharanitima, Pattharawin , Khoury, Nadeen , Cooper, Matthew , Cheungpasitporn, Wisit , Mao, Shennen A. , Cheungpasitporn, Wisit , Pattharanitima, Pattharawin , Cooper, Matthew , Khoury, Nadeen , Thongprayoon, Charat , Jadlowiec, Caroline C. , Mao, Michael A. , Bruminhent, Jackrapong , Garovic, Vesna D.

Mayo Clinic

JAMA Surgery | May 4, 2022 | Volume: 157 | Issue: 7 | Pages: e221286

10.1001/jamasurg.2022.1286 | PMID 35507356 Get It